Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Psoriasis: Update Bulletin # 1 [October 2018]

Product Code:
596201034
Publication Date:
October 2018
Format:
PDF
Price:
$1,095

This edition presents key opinion leader (KOL) views on recent developments in the treatment of psoriasis. Topics covered include; Bristol-Myers Squibb’s (BMS) initiation of two parallel Phase III studies comparing the investigational tyrosine kinase-2 (Tyk2) inhibitor BMS-986165 with placebo and the phosphodiesterase-4 (PDE4) inhibitor Otezla (apremilast; Celgene);  Lilly’s announcement of initiation of the Phase IV IXORA-R study, designed to illustrate the superiority of Taltz (ixekizumab) over Tremfya (guselkumab; Janssen Biotech/MorphoSys); the latest data presented at the European Academy of Dermatology and Venereology conference in September 2018 in respect of marketed therapies Tremfya, Otezla, Cosentyx (secukinumab; Novartis) and Siliq/Kyntheum (brodalumab; Bausch Health Companies/AstraZeneca/Leo Pharma), and the pipeline programmes, risankizumab (AbbVie; Boehringer Ingelheim) and bimekizumab (UCB).

Business Questions:

• Bristol-Myers Squibb (BMS) is developing the tyrosine kinase-2 (Tyk2) inhibitor BMS-986165: how do KOLs view this mechanism of action with respect to the treatment of psoriasis?
• Do KOLs have any concerns that Tyk2 inhibition will be associated with the adverse events seen with the Janus kinase (JAK) inhibitors?
• How well received is BMS’ Phase II data for BMS-986165? Do KOLs consider BMS-986165’s inferior potency to the biological therapies to be an issue for the future of this drug?
• What results are expected from the Phase III parallel trials POETYK-1 and POETYK-2, which are currently ongoing and are due to conclude in July 2020? Is the marketed oral therapy Otezla (apremilast; Celgene) a sufficient comparator to establish BMS-986165 as a viable treatment option?
• If approved, where in the current treatment paradigm will BMS-986165 be used? How successfully is it expected to compete with the current orally available product Otezla?
• What value do KOLs perceive in Lilly’s Phase IV IXORA-R clinical study, which aims to prove the superiority of Taltz (ixekizumab), an anti-interleukin-17 (anti-IL17) monoclonal antibody (mAb), over Tremfya (guselkumab; Janssen Biotech/MorphSys), an anti-IL23 mAb?
• How well designed is the IXORA-R study, and do KOLs believe that Lilly will be successful in proving superiority?
• What value do KOLs perceive in the new data presented at the European Academy of Dermatology and Venereology (EADV) conference in September 2018 in respect of marketed therapies Tremfya, Otezla, Cosentyx (secukinumab; Novartis) and Siliq/Kyntheum (brodalumab; Leo Pharma), and pipeline programmes for risankizumab (AbbVie), an anti-IL23 mAb, and bimekizumab (UCB), an anti-IL17 mAb?




customer.service@firstwordpharma.com

All Contents Copyright © 2018 Doctor's Guide Publishing Limited All Rights Reserved